- Home
- HBT vs PHAR Comparison
HBT vs PHAR Comparison
Compare HBT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- PHAR
- Stock Information
- Founded
- HBT 1920
- PHAR 1988
- Country
- HBT United States
- PHAR Netherlands
- Employees
- HBT N/A
- PHAR N/A
- Industry
- HBT Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- PHAR Health Care
- Exchange
- HBT Nasdaq
- PHAR Nasdaq
- Market Cap
- HBT 812.0M
- PHAR 951.7M
- IPO Year
- HBT 2019
- PHAR N/A
- Fundamental
- Price
- HBT $25.18
- PHAR $13.75
- Analyst Decision
- HBT Buy
- PHAR Strong Buy
- Analyst Count
- HBT 5
- PHAR 3
- Target Price
- HBT $28.63
- PHAR $30.00
- AVG Volume (30 Days)
- HBT 27.9K
- PHAR 10.7K
- Earning Date
- HBT 10-20-2025
- PHAR 11-06-2025
- Dividend Yield
- HBT 3.36%
- PHAR N/A
- EPS Growth
- HBT 12.74
- PHAR N/A
- EPS
- HBT 2.48
- PHAR N/A
- Revenue
- HBT $233,255,000.00
- PHAR $339,836,000.00
- Revenue This Year
- HBT $8.81
- PHAR $17.70
- Revenue Next Year
- HBT $20.52
- PHAR $12.25
- P/E Ratio
- HBT $10.09
- PHAR N/A
- Revenue Growth
- HBT 6.87
- PHAR 22.44
- 52 Week Low
- HBT $19.46
- PHAR $7.31
- 52 Week High
- HBT $27.02
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- HBT 54.25
- PHAR 46.62
- Support Level
- HBT $22.36
- PHAR $13.08
- Resistance Level
- HBT $25.33
- PHAR $14.81
- Average True Range (ATR)
- HBT 0.76
- PHAR 0.55
- MACD
- HBT 0.14
- PHAR -0.13
- Stochastic Oscillator
- HBT 94.95
- PHAR 29.12
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.